UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Jetstar to Charge for Overhead Cabin Bags From February 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
EXTON, Pa., March 12, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the year ended December 31, 2017 and recent operational highlights on Monday, March 19, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 800-239-9838 (domestic) or +1-323-794-2551 (international), and provide the conference code 6756079 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484-713-6133
[email protected]
